Open an account

MariMed

MRMD · OTC

$0.0555−$0.0015 (−2.63%)TodayMarket closed ·
Prev close $0.057

About MRMD

MariMed, Inc. engages in the cultivation, processing, and sale of branded cannabis products. The company is headquartered in Norwood, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2012-05-04. The firm develops, owns, and manages seed to sale of state-licensed cannabis facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. The company develops its own brands of premium cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other cannabis products, in domestic markets. Its products are developed in various consumption formats, including whole flower, pre-rolled flower, vape cartridges, concentrates, and edibles. The Company’s brands include Nature’s Heritage, a premium brand of cannabis flower, vapes, and concentrates; Betty’s Eddies, cannabis fruit chews that deliver better sleep, pain relief, stress relief, and more. The Betty's Eddies line also includes a cannabis-infused ice cream created in partnership with ice cream brand Emack & Bolio's.

Employees
808
Headquarters
Norwood, Massachusetts
Listed
May 4, 2012
Sector
Health Care
Industry
Pharmaceuticals
Website
ir.marimedinc.com

MRMD key statistics

Market cap
22.41M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
689.09K
Volume
131.65K
Open price
$0.056
High today
$0.059
Low today
$0.0526
52 Week high
$0.16
52 Week low
$0.055

MariMed (MRMD) at a glance

As of Oct 20, 2026, MariMed (MRMD) shares are priced at $0.0555, giving the company a market cap of 22.41M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0526 and $0.059. The current price is 5.5% above the day's low and 5.9% below its high.

Volume so far is 131.65K shares, below the average of 689.09K shares a day.

Over the past year MariMed has ranged from $0.055 to $0.16, and now sits 0% of the way up that range.

MariMed met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of -$0.0102.

MRMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 26.5% on average.

  1. Q3 FY24: reported $0.00 per share against an estimate of -$0.0102
  2. Q4 FY24: reported -$0.01 per share against an estimate of -$0.0102
  3. Q1 FY25: reported -$0.01 per share against an estimate of -$0.0102
  4. Q2 FY25: reported $0.00 per share against an estimate of -$0.0102
  5. Q3 FY25: reported -$0.01 per share against an estimate of -$0.0102
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0102
  7. Q1 FY26: reported -$0.01 per share against an estimate of -$0.0102
  8. Q2 FY26: reported -$0.01 per share against an estimate of -$0.0102

MRMD news

  • MariMed Q1 2026 Earnings Call: Complete Transcript

  • Press releaseGlobe Newswire

    MariMed Reports Second Quarter 2025 Earnings

  • Javier Hasse

    This Week In Cannabis: Earnings Divide The Market As DEA, Brands And Bills Move Forward

  • Javier Hasse

    The Week In Cannabis: Delays, Decrees And Deals Reshape The Global Playbook

  • Javier Hasse

    This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

  • Javier Hasse

    This Week In Cannabis: Snoop's Beverage Empire, Earnings, M&A, International News And More

  • Javier Hasse

    Cannabis Co. MariMed Finalizes $11M Deal To Acquire First State Compassion

  • Nicolás Jose Rodriguez

    Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?

Similar companies

Companies in the same industry as MariMed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.